Drug Trial Radar · NCT00078325
Armodafinil (CEP-10953) in Treatment of Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Syndrome(OSAHS)
Last checked: Nov 20, 2026Latest source record: Jul 19, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
395
Actual
Start
Feb 2004
Primary completion
Nov 2004
Study completion Nov 2004
Sponsor
- Lead sponsor
- CephalonIndustry
- Sponsor type
- Industry
- First posted
- Feb 25, 2004
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to determine whether treatment with Armodafinil (CEP-10953) is more effective than placebo treatment for patients with excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome (OSAHS) by measuring mean sleep latency from the Maintenance of Wakefulness Test (MWT) (30-minute version) (average of 4 naps at 0900, 1100, 1300, and 1500) and by Clinical Global Impression of Change (CGI-C) ratings (as related to general condition) at week 12, or last post-baseline visit.
Conditions
- Obstructive Sleep Apnea
- Hypopnea
Interventions
Armodafinil 250 mg/dayDrug
Armodafinil 250 mg once daily in the morning
Armodafinil 150 mg/dayDrug
Armodafinil 150 mg once daily in the morning
PlaceboDrug
Matching placebo tablets once daily in the morning
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maintenance of Wakefulness Test (MWT)Time frame: change from baseline at 12 weeks
- Clinical Global Impression of Change (CGI-C)Time frame: change from baseline at 12 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.